Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.43)
# 281
Out of 5,174 analysts
30
Total ratings
57.14%
Success rate
27.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Upgrades: Overweight | $8 → $27 | $21.33 | +26.58% | 1 | Mar 24, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $15 → $17 | $9.82 | +73.12% | 4 | Mar 17, 2026 | |
| GMAB Genmab | Initiates: Overweight | $40 | $25.68 | +55.76% | 1 | Mar 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $100 → $144 | $96.63 | +49.02% | 2 | Feb 26, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $46.04 | +15.12% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $21.41 | +7.43% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $41.41 | -15.48% | 1 | Feb 11, 2026 | |
| ZYME Zymeworks | Upgrades: Overweight | $25 → $33 | $24.02 | +37.39% | 4 | Dec 12, 2025 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $8 → $11 | $18.39 | -40.18% | 3 | Nov 11, 2025 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $60 | $30.35 | +97.69% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $27 | $12.05 | +124.07% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $31.64 | +39.06% | 1 | Jun 26, 2025 |
Sutro Biopharma
Mar 24, 2026
Upgrades: Overweight
Price Target: $8 → $27
Current: $21.33
Upside: +26.58%
Relay Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $15 → $17
Current: $9.82
Upside: +73.12%
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $25.68
Upside: +55.76%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $100 → $144
Current: $96.63
Upside: +49.02%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $46.04
Upside: +15.12%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $21.41
Upside: +7.43%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $41.41
Upside: -15.48%
Zymeworks
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $24.02
Upside: +37.39%
Bicara Therapeutics
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $18.39
Upside: -40.18%
Immunocore Holdings
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $30.35
Upside: +97.69%
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $12.05
Upside: +124.07%
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $31.64
Upside: +39.06%